Improving treatments for infections caused by drug-resistant Klebsiella bacteria
Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258
This study is working on creating better treatments using special antibodies that can fight against a tough bacteria called carbapenem-resistant Klebsiella pneumoniae, which can cause serious infections like pneumonia and sepsis, to help patients get better faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northport VA Medical Center NIH-funded |
| Lab location | 1 site (Northport, United States) |
| Project ID | NIH-11003778 on NIH RePORTER |
What this research studies
This research focuses on developing and optimizing monoclonal antibodies (mAbs) that target the capsule of carbapenem-resistant Klebsiella pneumoniae (CR-Kp), a dangerous bacteria responsible for severe infections like pneumonia and sepsis. The study aims to enhance the effectiveness of these antibodies, particularly against the diverse strains of CR-Kp that are prevalent in healthcare settings. By addressing the challenges of late diagnosis and the complexity of the bacterial capsule, the research seeks to provide a more effective treatment option for patients suffering from these infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with infections caused by carbapenem-resistant Klebsiella pneumoniae, particularly those with multiple comorbidities or those in healthcare settings.
Not a fit: Patients with infections caused by non-carbapenem-resistant bacteria or those who do not have access to healthcare facilities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with severe infections caused by drug-resistant bacteria, potentially reducing mortality rates.
How similar studies have performed: Other research has shown promise in developing monoclonal antibodies for similar bacterial infections, indicating that this approach has potential for success.
Where this research is happening
Northport, United States
- Northport VA Medical Center — Northport, United States (Active)
Researchers
- Principal investigator: Fries, Bettina — Northport VA Medical Center
- Study coordinator: Fries, Bettina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.